Endovascular Engineering Inc

Endovascular Engineering, Inc., also known as E2, is a privately held, venture-backed medical technology company founded in 2019 and headquartered in Menlo Park, California. The company is in its commercial stage, having raised an oversubscribed $80 million Series C financing round in April 2026 to support the launch of its main product. Investors include Gilde Healthcare, Norwest Venture Partners, Santé Ventures, and 415 Capital. Publicly available estimates suggest the company has fewer than 25 employees.

E2 develops and manufactures clot removal technologies for the treatment of venous thromboembolism (VTE), such as pulmonary embolism and deep vein thrombosis. Its flagship product is the Hēlo™ Thrombectomy System, a catheter-based device for the non-surgical removal of blood clots from veins and pulmonary arteries. The system features a patented dual-action mechanism that combines mechanical clot disruption with aspiration, and it utilizes a self-expanding funnel design intended to enable efficient, single-pass clot removal with a smaller catheter profile. The Hēlo system received FDA 510(k) clearance in late 2025.

As an operating company commercializing its own technology, Endovascular Engineering's patent litigation posture is that of a defendant. The company has been sued in one tracked patent case and has not initiated any patent lawsuits. This is consistent with a manufacturer being challenged by a competitor in the market.

The company's only tracked litigation is a patent infringement lawsuit filed by AngioDynamics, Inc. on April 23, 2026, in the U.S. District Court for the District of Delaware. The suit alleges that Endovascular Engineering's Hēlo Thrombectomy System infringes on AngioDynamics' patents, specifically citing its proprietary self-expanding funnel technology for thrombus removal. This legal challenge occurs within a competitive and active market for thrombectomy devices, which has seen several major acquisitions by large medical device firms.